Konruns

Zhitong · Oct 29, 2025 at 11:44 AM

Konruns released its performance for the first three quarters, with a net profit attributable to the parent company of 128 million yuan, a year-on-year increase of 13.19%

Zhitong · Oct 15, 2025 at 07:58 AM

Konruns: Plans to repurchase company shares for 50 million to 100 million yuan

Zhitong · Oct 14, 2025 at 01:11 AM

A-share innovative drug concept stocks fluctuated lower, with BETTA PHARMACEUTICALS falling over 10%, Jincheng Pharm, Konruns, Baillie Tianheng, Olymvax Biopharmaceuticals, and CCHT all dropping more than 5%

Zhitong · Sep 29, 2025 at 07:51 AM

Konruns: KC1036 combined with PD-1 antibody and platinum-based chemotherapy has been approved for clinical trials as a first-line treatment for advanced recurrent or metastatic esophageal squamous cell carcinoma

Zhitong · Sep 25, 2025 at 12:43 AM

Innovative drug concept stocks surged and then fell back, with Mengke Pharmaceutical dropping over 10%, BrightGene, Bio-S falling over 7%, and YKYY, Konruns, EASTON BIOPHARMACEUTICALS, Fushine among those with the largest declines

Zhitong · Sep 14, 2025 at 08:43 PM

Innovative drug concept stocks fluctuate and rise, DEZHAN HEALTHCARE hits the limit up